BeOne Medicines (ONC) EBT (2015 - 2026)
BeOne Medicines (ONC) posted quarterly EBT of $259.2 million for Q1 2026, up 1140.26% year-over-year from $20.9 million in Q1 2025, and up 73.69% quarter-over-quarter from $149.2 million in Q4 2025.
BeOne Medicines (ONC) EBT (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported EBT for 12 consecutive years, with $259.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 1140.26% year-over-year to $259.2 million; the TTM figure through Mar 2026 stood at $655.2 million (up 343.85% YoY), while the FY2025 annual figure was $416.9 million, up 178.21% from the prior year.
- EBT rose to $259.2 million in Q1 2026 per ONC's latest filing, from $149.2 million in the prior quarter.
- Across five years, EBT topped out at $259.2 million in Q1 2026 and bottomed at -$557.6 million in Q2 2022.
- Historically, EBT has averaged -$155.5 million across 5 years, with a median of -$105.9 million in 2024.
- Annual changes were most pronounced in 2022 — EBT slumped 780.92% — and 2026, when it surged 1140.26%.
- BeOne Medicines' EBT stood at -$431.0 million in 2022, then advanced by 18.61% to -$350.8 million in 2023, then jumped by 75.67% to -$85.4 million in 2024, then surged by 274.86% to $149.2 million in 2025, then jumped by 73.69% to $259.2 million in 2026.
- Business Quant data shows ONC's EBT at $259.2 million in Q1 2026, $149.2 million in Q4 2025, and $147.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -294.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 312.46 Mn |
| Mar 31, 2026 | 259.22 Mn |
| Dec 31, 2025 | 149.24 Mn |
| Sep 30, 2025 | 147.16 Mn |
| Jun 30, 2025 | 99.55 Mn |
| Mar 31, 2025 | 20.90 Mn |
| Dec 31, 2024 | -85.35 Mn |
| Sep 30, 2024 | -98.30 Mn |
| Jun 30, 2024 | -105.92 Mn |
| Mar 31, 2024 | -243.43 Mn |
| Dec 31, 2023 | -350.77 Mn |
| Sep 30, 2023 | 229.34 Mn |
| Jun 30, 2023 | -367.46 Mn |
| Mar 31, 2023 | -336.94 Mn |
| Dec 31, 2022 | -430.97 Mn |
| Sep 30, 2022 | -551.24 Mn |
| Jun 30, 2022 | -557.59 Mn |
| Mar 31, 2022 | -421.25 Mn |
| Dec 31, 2021 | -606.03 Mn |
| Sep 30, 2021 | -433.08 Mn |